|
VAQTA can be easily integrated into
any of these visits
aA booster dose of VAQTA (~25U/0.5
mL) should be given 6 to 18 months (a 12-month window)
after the primary dose. However, because protection may
not be achieved until
completion of the series, the 2nd dose should be given as soon as possible after
the minimum interval (6 months).
VAQTA is indicated for active immunization against disease
caused by hepatitis A virus (HAV) in persons 12 months of
age and older. Primary immunization should be given at least
2 weeks prior to expected exposure
to HAV.
The dosing regimen for VAQTA 0.5 mL (~25U) consists of 2
doses, the first given at 12 months to 18 years of age, and
a booster dose given 6 to 18 months afterward.
Select safety information
VAQTA is contraindicated in individuals who are hypersensitive
to any component of the vaccine. Hepatitis A vaccine should
not be administered to persons with a history of a severe
reaction to a prior dose of hepatitis A vaccine or to a vaccine
component.
Individuals who develop symptoms suggestive of
hypersensitivity after an injection of hepatitis A vaccine
should not receive
further injections of the vaccine.
In combined clinical trials
involving healthy children 12 to 23 months of age and children
and adolescents 2 to 18
years of age, the most commonly reported complaints (>2%
of injections) in one or both of these groups were localized
injection-site reactions (pain/tenderness/soreness, warmth,
erythema, swelling), fever, diarrhea, vomiting, irritability,
upper respiratory infection, rhinorrhea, cough, rash, otitis
media, and headache.
An acute infection or febrile illness
may be reason for delaying use of VAQTA except when, in
the opinion of a physician,
withholding the vaccine entails a greater risk.
As with
any vaccine, vaccination with VAQTA may not result in a
protective response in all susceptible vaccinees. Before administering VAQTA, please read the Prescribing
Information.
|
